Ulrich M. Lauer,Michael Bitzer,Johanna Lampe,Martina Zimmermann,Susanne Berchtold,Sebastian Lange,Wolfgang J. Neubert,Sascha Bossow
申请号：
US13818053
公开号：
US20130217757A1
申请日:
2011.08.19
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.
